Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer.
Adolescent
Adult
Age Factors
Age of Onset
Antineoplastic Agents, Immunological
/ adverse effects
Child
Drug-Related Side Effects and Adverse Reactions
/ diagnosis
Hematopoietic Stem Cell Transplantation
/ adverse effects
Humans
Immunologic Factors
/ adverse effects
Immunotherapy
/ adverse effects
Neoplasms
/ diagnosis
Receptors, Chimeric Antigen
/ immunology
Severity of Illness Index
Transfusion Reaction
/ diagnosis
Transfusion-Related Acute Lung Injury
/ diagnosis
Young Adult
Journal
Nature reviews. Clinical oncology
ISSN: 1759-4782
Titre abrégé: Nat Rev Clin Oncol
Pays: England
ID NLM: 101500077
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
accepted:
13
01
2021
pubmed:
21
2
2021
medline:
18
9
2021
entrez:
20
2
2021
Statut:
ppublish
Résumé
Cancer immunotherapies are associated with remarkable therapeutic response rates but also with unique and severe toxicities, which potentially result in rapid deterioration in health. The number of clinical applications for novel immune effector-cell therapies, including chimeric antigen receptor (CAR)-expressing cells, and other immunotherapies, such as immune-checkpoint inhibitors, is increasing. In this Consensus Statement, members of the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network Hematopoietic Cell Transplantation-Cancer Immunotherapy (HCT-CI) Subgroup, Paediatric Diseases Working Party (PDWP) of the European Society of Blood and Marrow Transplantation (EBMT), Supportive Care Committee of the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) and MD Anderson Cancer Center CAR T Cell Therapy-Associated Toxicity (CARTOX) Program collaborated to provide updated comprehensive recommendations for the care of children, adolescents and young adults receiving cancer immunotherapies. With these recommendations, we address emerging toxicity mitigation strategies, we advocate for the characterization of baseline organ function according to age and discipline-specific criteria, we recommend early critical care assessment when indicated, with consideration of reversibility of underlying pathology (instead of organ failure scores) to guide critical care interventions, and we call for researchers, regulatory agencies and sponsors to support and facilitate early inclusion of young patients with cancer in well-designed clinical trials.
Identifiants
pubmed: 33608690
doi: 10.1038/s41571-021-00474-4
pii: 10.1038/s41571-021-00474-4
pmc: PMC9393856
mid: NIHMS1829870
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Immunologic Factors
0
Receptors, Chimeric Antigen
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
435-453Subventions
Organisme : NHLBI NIH HHS
ID : K23 HL150244
Pays : United States
Organisme : NIBIB NIH HHS
ID : R01 EB026291
Pays : United States
Commentaires et corrections
Type : ErratumIn
Références
Palmer, S., Patterson, P. & Thompson, K. A national approach to improving adolescent and young adult (AYA) oncology psychosocial care: the development of AYA-specific psychosocial assessment and care tools. Palliat. Support. Care 12, 183–188 (2014).
pubmed: 23659778
Mahadeo, K. M. et al. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat. Rev. Clin. Oncol. 16, 45–63 (2019).
pubmed: 30082906
Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transpl. 25, 625–638 (2019).
FDA. Highlights of Prescribing Information: KYMRIAH. https://www.fda.gov/files/vaccines,%20blood%20&%20biologics/published/Package-Insert---KYMRIAH.pdf (2018).
FDA. Highlights of Prescribing Information: YESCARTA. https://www.fda.gov/media/108377/download (2020).
FDA. Highlights of Prescribing Information: TECARTUS. https://www.fda.gov/media/140409/download (2020).
Brudno, J. N. & Kochenderfer, J. N. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127, 3321–3330 (2016).
pubmed: 27207799
pmcid: 4929924
Li, D. et al. Genetically engineered T cells for cancer immunotherapy. Signal. Transduct. Target. Ther. 4, 35 (2019).
pubmed: 31637014
pmcid: 6799837
Johnson, L. A. & June, C. H. Driving gene-engineered T cell immunotherapy of cancer. Cell Res. 27, 38–58 (2017).
pubmed: 28025979
Baiden-Amissah, R. E. M. & Tuyaerts, S. Contribution of aging, obesity, and microbiota on tumor immunotherapy efficacy and toxicity. Int. J. Mol. Sci. 20, 3586 (2019).
pmcid: 6678743
Ruella, M. & Maus, M. V. Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies. Comput. Struct. Biotechnol. J. 14, 357–362 (2016).
pubmed: 27761200
pmcid: 5061074
Fousek, K. et al. CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression. Leukemia 35, 75–89 (2021).
pubmed: 32205861
György, B. Bispecific CAR T cells have a dual grasp on tumors. Sci. Transl. Med. 12, eabf2636 (2020).
Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545–553 (2020).
pubmed: 32023374
pmcid: 7101242
Ghorashian, S. et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat. Med. 25, 1408–1414 (2019).
pubmed: 31477906
Benjamin, R. et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet 396, 1885–1894 (2020).
pubmed: 33308471
Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell 140, 883–899 (2010).
pubmed: 20303878
pmcid: 2866629
Scott, M. C. et al. Comparative transcriptome analysis quantifies immune cell transcript levels, metastatic progression, and survival in osteosarcoma. Cancer Res. 78, 326–337 (2018).
pubmed: 29066513
Serrels, A. et al. Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity. Cell 163, 160–173 (2015).
pubmed: 26406376
pmcid: 4597190
Rosenberg, S. A. et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N. Engl. J. Med. 319, 1676–1680 (1988).
pubmed: 3264384
Lizee, G. et al. Harnessing the power of the immune system to target cancer. Annu. Rev. Med. 64, 71–90 (2013).
pubmed: 23092383
Gattinoni, L., Powell, D. J. Jr., Rosenberg, S. A. & Restifo, N. P. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6, 383–393 (2006).
pubmed: 16622476
pmcid: 1473162
Wang, Z., Li, B., Ren, Y. & Ye, Z. T-cell-based immunotherapy for osteosarcoma: challenges and opportunities. Front. Immunol. 7, 353 (2016).
pubmed: 27683579
pmcid: 5021687
Rosenberg, S. A. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550–4557 (2011).
pubmed: 21498393
pmcid: 3131487
Dudley, M. E. et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850–854 (2002).
pubmed: 12242449
pmcid: 1764179
Rosenberg, S. A. et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl Cancer Inst. 86, 1159–1166 (1994).
pubmed: 8028037
Parkhurst, M. R. et al. Unique neoantigens arise from somatic mutations in patients with gastrointestinal cancers. Cancer Discov. 9, 1022–1035 (2019).
pubmed: 31164343
pmcid: 7138461
Turajlic, S. et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 18, 1009–1021 (2017).
pubmed: 28694034
Olle Hurtado, M. et al. Tumor infiltrating lymphocytes expanded from pediatric neuroblastoma display heterogeneity of phenotype and function. PLoS ONE 14, e0216373 (2019).
pubmed: 31398192
pmcid: 6688820
Mullinax, J. E. et al. Combination of ipilimumab and adoptive cell therapy with tumor-infiltrating lymphocytes for patients with metastatic melanoma. Front. Oncol. 8, 44 (2018).
pubmed: 29552542
pmcid: 5840208
Zhao, Q. et al. Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile. J. Immunother. Cancer 7, 154 (2019).
pubmed: 31208461
pmcid: 6580640
Nguyen, L. T. et al. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2. Cancer Immunol. Immunother. 68, 773–785 (2019).
pubmed: 30747243
Schwinger, W. et al. Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients. Ann. Oncol. 16, 1199–1206 (2005).
pubmed: 15849223
Yeh, S. et al. Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology 116, 981–989.e1 (2009).
pubmed: 19410956
Robbins, P. F. et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin. Cancer Res. 21, 1019–1027 (2015).
pubmed: 25538264
Morgan, R. A. et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36, 133–151 (2013).
pubmed: 23377668
pmcid: 3581823
Linette, G. P. et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122, 863–871 (2013).
pubmed: 23770775
pmcid: 3743463
Chodon, T. et al. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin. Cancer Res. 20, 2457–2465 (2014).
pubmed: 24634374
pmcid: 4070853
Tawara, I. et al. Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS. Blood 130, 1985–1994 (2017).
pubmed: 28860210
Rezvani, K., Rouce, R., Liu, E. & Shpall, E. Engineering natural killer cells for cancer immunotherapy. Mol. Ther. 25, 1769–1781 (2017).
pubmed: 28668320
pmcid: 5542803
Khatua, S. et al. Phase I study of intraventricular infusions of autologous ex-vivo-expanded NK cells in children with recurrent medulloblastoma and ependymoma. Neuro Oncol. 22, 1214–1225 (2020).
pubmed: 32152626
pmcid: 7594549
Screpanti, V., Wallin, R. P., Ljunggren, H. G. & Grandien, A. A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells. J. Immunol. 167, 2068–2073 (2001).
pubmed: 11489989
Vela, M. et al. Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia. Cancer Lett. 422, 107–117 (2018).
pubmed: 29477379
Rubnitz, J. E. et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J. Clin. Oncol. 28, 955–959 (2010).
pubmed: 20085940
pmcid: 2834435
Nguyen, R. et al. A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia. J. Immunother. Cancer 7, 81 (2019).
pubmed: 30894213
pmcid: 6425674
Cho, D. et al. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin. Cancer Res. 16, 3901–3909 (2010).
pubmed: 20542985
pmcid: 3168562
Fernandez, L. et al. Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner. Cancer Lett. 368, 54–63 (2015).
pubmed: 26276724
Shah, N. N. et al. Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation. Blood 125, 784–792 (2015).
pubmed: 25452614
pmcid: 4311226
Pérez-Martínez, A. et al. Natural killer cells can exert a graft-vs-tumor effect in haploidentical stem cell transplantation for pediatric solid tumors. Exp. Hematol. 40, 882–891.e1 (2012).
pubmed: 22771496
Kimpo, M. S., Oh, B. & Lee, S. The role of natural killer cells as a platform for immunotherapy in pediatric cancers. Curr. Oncol. Rep. 21, 93 (2019).
pubmed: 31502008
pmcid: 6733832
Denman, C. J. et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS ONE 7, e30264 (2012).
pubmed: 22279576
pmcid: 3261192
Andersen, M. H., Schrama, D., thor Straten, P. & Becker, J. C. Cytotoxic T cells. J. Invest. Dermatol. 126, 32–41 (2006).
pubmed: 16417215
Van Pel, A. & Boon, T. Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc. Natl Acad. Sci. USA 79, 4718–4722 (1982).
pubmed: 6981814
pmcid: 346748
Castelli, C. et al. T-cell recognition of melanoma-associated antigens. J. Cell. Physiol. 182, 323–331 (2000).
pubmed: 10653598
Liu, Z. et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas. Recent. Results Cancer Res. 159, 123–133 (2002).
pubmed: 11785836
Prockop, S. et al. Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. J. Clin. Invest. 130, 733–747 (2020).
pubmed: 31689242
pmcid: 6994129
Moosmann, A. et al. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood 115, 2960–2970 (2010).
pubmed: 20103780
Prockop, S. E. et al. A multicenter, open label, phase 3 study of tabelecleucel for solid organ transplant subjects with Epstein-Barr virus-driven post-transplant lymphoproliferative disorder (EBV+PTLD) after failure of rituximab or rituximab and chemotherapy (ALLELE) [abstract]. Biol. Blood Marrow Transpl. 26, S274 (2020).
Prockop, S. E. et al. Long-term outcomes of patients with epstein-barr virus-driven post-transplant lymphoproliferative disease following solid organ transplant or allogeneic hematopoietic cell transplant treated with tabelecleucel in a multicenter expanded access program study [abstract]. Biol. Blood Marrow Transpl. 26, S61–S62 (2020).
Bollard, C. M. et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+Hodgkin’s disease. J. Exp. Med. 200, 1623–1633 (2004).
pubmed: 15611290
pmcid: 2211993
Straathof, K. C. et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 105, 1898–1904 (2005).
pubmed: 15542583
Schuessler, A. et al. Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res. 74, 3466–3476 (2014).
pubmed: 24795429
Leen, A. M. et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 121, 5113–5123 (2013).
pubmed: 23610374
pmcid: 3695359
Gottschalk, S. & Rooney, C. M. Adoptive T-cell immunotherapy. Curr. Top. Microbiol. Immunol. 391, 427–454 (2015).
pubmed: 26428384
pmcid: 4655436
Muftuoglu, M. et al. Allogeneic BK virus-specific T cells for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 379, 1443–1451 (2018).
pubmed: 30304652
pmcid: 6283403
Pello, O. M. et al. BKV-specific T cells in the treatment of severe refractory haemorrhagic cystitis after HLA-haploidentical haematopoietic cell transplantation. Eur. J. Haematol. 98, 632–634 (2017).
pubmed: 28083990
Huehls, A. M., Coupet, T. A. & Sentman, C. L. Bispecific T-cell engagers for cancer immunotherapy. Immunol. Cell Biol. 93, 290–296 (2015).
pubmed: 25367186
FDA. Highlights of Prescribing Information: Blincyto. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125557s013lbl.pdf (2018).
Boussiotis, V. A. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N. Engl. J. Med. 375, 1767–1778 (2016).
pubmed: 27806234
pmcid: 5575761
Toor, S. M. & Elkord, E. Therapeutic prospects of targeting myeloid-derived suppressor cells and immune checkpoints in cancer. Immunol. Cell Biol. 96, 888–897 (2018).
pubmed: 29635843
Hargadon, K. M., Johnson, C. E. & Williams, C. J. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int. Immunopharmacol. 62, 29–39 (2018).
pubmed: 29990692
Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
pubmed: 20525992
pmcid: 3549297
Merchant, M. S. et al. Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors. Clin. Cancer Res. 22, 1364–1370 (2016).
pubmed: 26534966
Geoerger, B. et al. Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma. Eur. J. Cancer 86, 358–363 (2017).
pubmed: 29100190
Davis, K. L. et al. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol. 21, 541–550 (2020).
pubmed: 32192573
pmcid: 7255545
Overman, M. J. et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 18, 1182–1191 (2017).
pubmed: 28734759
pmcid: 6207072
Overman, M. J. et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J. Clin. Oncol. 36, 773–779 (2018).
pubmed: 29355075
Geoerger, B. et al. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Lancet Oncol. 21, 121–133 (2020).
pubmed: 31812554
Goldberg, S. B. et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 21, 655–663 (2020).
pubmed: 32251621
pmcid: 7380514
Kawazoe, A. et al. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial. Lancet Oncol. 21, 1057–1065 (2020).
pubmed: 32589866
Grosser, R., Cherkassky, L., Chintala, N. & Adusumilli, P. S. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell 36, 471–482 (2019).
pubmed: 31715131
pmcid: 7171534
Ghosh, A. K. et al. CAR T cell therapy-related cardiovascular outcomes and management: systemic disease or direct cardiotoxicity? JACC 2, 97–109 (2020).
pubmed: 34396213
pmcid: 8352125
Feng, Y. et al. Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin. Cancer Res. 19, 3977–3986 (2013).
pubmed: 23741070
Ihara, K. Immune checkpoint inhibitor therapy for pediatric cancers: a mini review of endocrine adverse events. Clin. Pediatr. Endocrinol. 28, 59–68 (2019).
pubmed: 31384097
pmcid: 6646237
Neelapu, S. S. et al. Chimeric antigen receptor T-cell therapy – assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15, 47–62 (2018).
pubmed: 28925994
Brahmer, J. R. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 36, 1714–1768 (2018).
pubmed: 29442540
Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439–448 (2018).
pubmed: 29385370
pmcid: 5996391
Queudeville, M. et al. Blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Eur. J. Haematol. https://doi.org/10.1111/ejh.13569 (2020).
doi: 10.1111/ejh.13569
Berg, M. D. et al. Part 13: Pediatric basic life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 122, S862–S875 (2010).
pubmed: 20956229
pmcid: 3717258
Gutierrez, C. et al. Critical care management of toxicities associated with targeted agents and immunotherapies for cancer. Crit. Care Med. 48, 10–21 (2020).
pubmed: 31725440
pmcid: 7505092
Fitzgerald, J. C. et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit. Care Med. 45, e124–e131 (2017).
pubmed: 27632680
pmcid: 5452983
Roy, J. P. & Devarajan, P. Acute kidney injury: diagnosis and management. Indian J. Pediatr. 87, 600–607 (2020).
pubmed: 31713215
Fragasso, T., Ricci, Z. & Goldstein, S. L. in Contributions to Nephrology (eds Ding, X., Rosner, M. H. & Ronco, C.) 113–126 (Karger, 2018). [Series Ed. Ronco, C. Acute Kidney Injury - Basic Research and Clinical Practice Vol. 193]
Menon, S. et al. Urinary biomarker incorporation into the renal angina index early in intensive care unit admission optimizes acute kidney injury prediction in critically ill children: a prospective cohort study. Nephrol. Dial. Transpl. 31, 586–594 (2016).
Bottari, G. et al. Multimodal therapeutic approach of cytokine release syndrome developing in a child given chimeric antigen receptor-modified T cell infusion. Crit. Care Explor. 2, e0071 (2020).
pubmed: 32166291
pmcid: 7063902
Gutgarts, V. et al. Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery. Biol. Blood Marrow Transpl. 26, 1071–1076 (2020).
Gupta, S. et al. Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma. Am. J. Kidney Dis. 76, 63–71 (2020).
pubmed: 31973908
pmcid: 7311244
Gutierrez, C. et al. The chimeric antigen receptor–intensive care unit (CAR-ICU) initiative: surveying intensive care unit practices in the management of CAR T-cell associated toxicities. J. Crit. Care 58, 58–64 (2020).
pubmed: 32361219
pmcid: 7321897
Dubois, M. J. et al. Albumin administration improves organ function in critically ill hypoalbuminemic patients: a prospective, randomized, controlled, pilot study. Crit. Care Med. 34, 2536–2540 (2006).
pubmed: 16915107
Hariri, G. et al. Albumin infusion improves endothelial function in septic shock patients: a pilot study. Intensive Care Med. 44, 669–671 (2018).
pubmed: 29392345
Hu, Y., Feng, J., Shao, M. & Huang, H. Profile of capillary-leak syndrome in patients received chimeric antigen receptor T cell therapy [abstract]. Blood 132 (Suppl. 1), 5204 (2018).
Milesi, C. et al. High-flow nasal cannula: recommendations for daily practice in pediatrics. Ann. Intensive Care 4, 29 (2014).
pubmed: 25593745
pmcid: 4273693
Dysart, K., Miller, T. L., Wolfson, M. R. & Shaffer, T. H. Research in high flow therapy: mechanisms of action. Respir. Med. 103, 1400–1405 (2009).
pubmed: 19467849
McDonald, C. F. Low-flow oxygen: how much is your patient really getting? Respirology 19, 469–470 (2014).
pubmed: 24698706
Kwon, J. W. High-flow nasal cannula oxygen therapy in children: a clinical review. Clin. Exp. Pediatr. 63, 3–7 (2020).
pubmed: 31999912
Hutchings, F. A., Hilliard, T. N. & Davis, P. J. Heated humidified high-flow nasal cannula therapy in children. Arch. Dis. Child. 100, 571–575 (2015).
pubmed: 25452315
Weiler, T. et al. The relationship between high flow nasal cannula flow rate and effort of breathing in children. J. Pediatr. 189, 66–71.e3 (2017).
pubmed: 28669609
Morley, S. L. Non-invasive ventilation in paediatric critical care. Paediatr. Respir. Rev. 20, 24–31 (2016).
pubmed: 27118355
Morris, J. V., Kapetanstrataki, M., Parslow, R. C., Davis, P. J. & Ramnarayan, P. Patterns of use of heated humidified high-flow nasal cannula therapy in PICUs in the United Kingdom and Republic of Ireland. Pediatr. Crit. Care Med. 20, 223–232 (2019).
pubmed: 30395107
Mestermann, K. et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Sci. Transl. Med. 11, eaau5907 (2019).
pubmed: 31270272
pmcid: 7523030
Philip, B. RQR8: A universal safety switch for cellular therapies. Thesis, University College London (2015).
Gardner, R. A. et al. Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood 134, 2149–2158 (2019).
pubmed: 31697826
pmcid: 6908832
Kadauke, S. et al. Early administration of tocilizumab (Toci) for the prevention of grade 4 cytokine release syndrome (CRS) after CD19-directed CAR T-cell therapy (CTL019) [abstract]. Cytotherapy 21, e2–e3 (2019).
Yanez, L., Sanchez-Escamilla, M. & Perales, M. A. CAR T cell toxicity: current management and future directions. Hemasphere 3, e186 (2019).
pubmed: 31723825
pmcid: 6746032
Schuster, S. J. et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N. Engl. J. Med. 377, 2545–2554 (2017).
pubmed: 29226764
pmcid: 5788566
Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017).
pubmed: 29226797
pmcid: 5882485
Mahadeo, K. M. et al. Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement. Lancet Haematol. 7, e61–e72 (2020).
pubmed: 31818728
Gust, J. et al. Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy. Ann. Neurol. 86, 42–54 (2019).
pubmed: 31074527
Gust, J. et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 7, 1404–1419 (2017).
pubmed: 29025771
pmcid: 5718945
Santomasso, B. D. et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 8, 958–971 (2018).
pubmed: 29880584
pmcid: 6385599
Miettunen, P. M., Narendran, A., Jayanthan, A., Behrens, E. M. & Cron, R. Q. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology 50, 417–419 (2011).
pubmed: 20693540
Henter, J. I. et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 48, 124–131 (2007).
pubmed: 16937360
Brudno, J. N. et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J. Clin. Oncol. 34, 1112–1121 (2016).
pubmed: 26811520
pmcid: 4872017
Glucksberg, H. et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18, 295–304 (1974).
pubmed: 4153799
Jacobsohn, D. Acute graft-versus-host disease in children. Bone Marrow Transplant. 41, 215–221 (2008).
pubmed: 17934526
Harris, A. C. et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol. Blood Marrow Transpl. 22, 4–10 (2016).
Li, X., Shao, C., Shi, Y. & Han, W. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. J. Hematol. Oncol. 11, 31 (2018).
pubmed: 29482595
pmcid: 6389077
Liu, Y. H. et al. Diagnosis and management of immune related adverse events (irAEs) in cancer immunotherapy. Biomed. Pharmacother. 120, 109437 (2019).
pubmed: 31590992
Khan, M. et al. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. Medicine 97, e11936 (2018).
pubmed: 30113497
pmcid: 6113026
de La Rochefoucauld, J., Noel, N. & Lambotte, O. Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach. Intern. Emerg. Med. 15, 587–598 (2020).
Weber, J. S., Kahler, K. C. & Hauschild, A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 30, 2691–2697 (2012).
pubmed: 22614989
Li, A. M. et al. Checkpoint inhibitors augment CD19-directed chimeric antigen receptor (CAR) T cell therapy in relapsed B-cell acute lymphoblastic leukemia [abstract]. Blood 132 (Suppl. 1), 556 (2018).
Bajciova, V. Therapeutic effect and tolerance of ipilimumam in metastatic malignant melanoma in children – a case report. Klin. Onkol. 28, 4S115–4S120 (2015).
pubmed: 26647899
Blumenthal, D. T. et al. Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors. J. Neurooncol 129, 453–460 (2016).
pubmed: 27377654
Bouffet, E. et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J. Clin. Oncol. 34, 2206–2211 (2016).
pubmed: 27001570
Foran, A. E., Nadel, H. R., Lee, A. F., Savage, K. J. & Deyell, R. J. Nivolumab in the treatment of refractory pediatric Hodgkin lymphoma. J. Pediatr. Hematol. Oncol. 39, e263–e266 (2017).
pubmed: 27841828
Shad, A. T. et al. Tolerance and effectiveness of nivolumab after pediatric T-cell replete, haploidentical, bone marrow transplantation: a case report. Pediatr. Blood Cancer 64, e26257 (2017).
Zhu, X. et al. Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: case report. J. Neurosurg. Pediatr. 19, 249–253 (2017).
pubmed: 27858578
Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 378, 158–168 (2018).
pubmed: 29320654
Weber, J. S., Yang, J. C., Atkins, M. B. & Disis, M. L. Toxicities of immunotherapy for the practitioner. J. Clin. Oncol. 33, 2092–2099 (2015).
pubmed: 25918278
pmcid: 4881375
Trinh, S., Le, A., Gowani, S. & La-Beck, N. M. Management of immune-related adverse events associated with immune checkpoint inhibitor therapy: a minireview of current clinical guidelines. Asia Pac. J. Oncol. Nurs. 6, 154–160 (2019).
pubmed: 30931360
pmcid: 6371672
Livingston, E. H. & Lee, S. Percentage of burned body surface area determination in obese and nonobese patients. J. Surg. Res. 91, 106–110 (2000).
pubmed: 10839957
Ham, P. & Allen, C. Adolescent health screening and counseling. Am. Fam. Phys. 86, 1109–1116 (2012).
Clotman, K., Janssens, K., Specenier, P., Weets, I. & De Block, C. E. M. Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus. J. Clin. Endocrinol. Metab. 103, 3144–3154 (2018).
pubmed: 29955867
Stamatouli, A. M. et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes 67, 1471–1480 (2018).
pubmed: 29937434
pmcid: 6054443
Sakamoto, K., Fukihara, J., Morise, M. & Hashimoto, N. Clinical burden of immune checkpoint inhibitor-induced pneumonitis. Respir. Investig. 58, 305–319 (2020).
pubmed: 32713811
Naidoo, J. et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J. Clin. Oncol. 35, 709–717 (2017).
pubmed: 27646942
Rashdan, S., Minna, J. D. & Gerber, D. E. Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. Lancet Respir. Med. 6, 472–478 (2018).
pubmed: 29856320
pmcid: 7341891
Khwaja, A. KDIGO clinical practice guideline for acute kidney injury. Nephron. Clin. Pract. 120, c179–c184 (2012).
pubmed: 22890468
Gupta, S., Cortazar, F. B., Riella, L. V. & Leaf, D. E. Immune checkpoint inhibitor nephrotoxicity: update 2020. Kidney360 1, 130–140 (2020).
pubmed: 35372904
pmcid: 8809100
Ma, Y., Wang, Q., Dong, Q., Zhan, L. & Zhang, J. How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy. Am. J. Cancer Res. 9, 1546–1553 (2019).
pubmed: 31497342
pmcid: 6726978
Ferrara, R. et al. Do immune checkpoint inhibitors need new studies methodology? J. Thorac. Dis. 10, S1564–S1580 (2018).
pubmed: 29951307
pmcid: 5994495
Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009).
pubmed: 19097774
Nishino, M. et al. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin. Cancer Res. 19, 3936–3943 (2013).
pubmed: 23743568
pmcid: 3740724
Pignon, J.-C. et al. irRECIST for the evaluation of candidate biomarkers of response to nivolumab in metastatic clear cell renal cell carcinoma: analysis of a phase II prospective clinical trial. Clin. Cancer Res. 25, 2174–2184 (2019).
pubmed: 30670497
pmcid: 6445699
Seymour, L. et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 18, e143–e152 (2017).
pubmed: 28271869
pmcid: 5648544
Wolchok, J. D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412–7420 (2009).
pubmed: 19934295
Lee, J. H. et al. Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies. JAMA Oncol. 4, 717–721 (2018).
pubmed: 29423503
pmcid: 5885201
Okada, H. et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 16, e534–e542 (2015).
pubmed: 26545842
pmcid: 4638131
Di Giacomo, A. M. et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol. Immunother. 58, 1297–1306 (2009).
pubmed: 19139884
Masuhiro, K., Shiroyama, T., Nagatomo, I. & Kumanogoh, A. Unique case of pseudoprogression manifesting as lung cavitation after pembrolizumab treatment. J. Thorac. Oncol. 14, e108–e109 (2019).
pubmed: 31027746
Tanizaki, J. et al. Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression. Lung Cancer 102, 44–48 (2016).
pubmed: 27987588
Hochmair, M. J., Schwab, S., Burghuber, O. C., Krenbek, D. & Prosch, H. Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy. Lung Cancer 113, 4–6 (2017).
pubmed: 29110847
Kohorst, M. A. et al. Transfusion reactions in pediatric and adolescent young adult haematology oncology and immune effector cell patients. EClinicalMedicine 26, 100514 (2020).
pubmed: 32964199
pmcid: 7490993
Kim, J., Park, J. H. & Shin, S. Effectiveness of simulation-based nursing education depending on fidelity: a meta-analysis. BMC Med. Educ. 16, 152 (2016).
pubmed: 27215280
pmcid: 4877810
Okuda, Y. et al. The utility of simulation in medical education: what is the evidence? Mt. Sinai J. Med. 76, 330–343 (2009).
pubmed: 19642147
Azoulay, E., Shimabukuro-Vornhagen, A., Darmon, M. & von Bergwelt-Baildon, M. Critical care management of chimeric antigen receptor T cell-related toxicity. Be aware and prepared. Am. J. Respir. Crit. Care Med. 200, 20–23 (2019).
pubmed: 30676776
r ICU resource utilization in critically ill patients following chimeric antigen receptor T-cell therapy. Am. J. Respir Crit. Care Med. 202, 1184–1187 (2020).
Redelman-Sidi, G. et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors). Clin. Microbiol. Infect. 24, S95–S107 (2018).
pubmed: 29427804
pmcid: 5971148
Davies, H. D. & Committee on Infectious Diseases. Infectious complications with the use of biologic response modifiers in infants and children. Pediatrics 138, e20161209 (2016).
pubmed: 27432853
Hill, J. A. & Seo, S. K. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood 136, 925–935 (2020).
pubmed: 32582924
pmcid: 7441168
Fishman, J. A., Hogan, J. I. & Maus, M. V. Inflammatory and infectious syndromes associated with cancer immunotherapies. Clin. Infect. Dis. 69, 909–920 (2019).
pubmed: 30520987
Yakoub-Agha, I. et al. Management of adults and children undergoing CAR T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica 105, 297–316 (2019).
Kelly, D. F. et al. Plasma and memory B-cell kinetics in infants following a primary schedule of CRM 197-conjugated serogroup C meningococcal polysaccharide vaccine. Immunology 127, 134–143 (2009).
pubmed: 19175802
pmcid: 2678189
Perez, E. E. et al. Update on the use of immunoglobulin in human disease: a review of evidence. J. Allergy Clin. Immunol. 139, S1–S46 (2017).
pubmed: 28041678
Tomblyn, M. et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol. Blood Marrow Transpl. 15, 1143–1238 (2009).
Hu, Y. et al. CAR T-cell treatment during the COVID-19 pandemic: management strategies and challenges. Curr. Res. Transl. Med. 68, 111–118 (2020).
pubmed: 32620465
pmcid: 7321051
Bisogno, G. et al. Clinical characteristics and outcome of severe acute respiratory syndrome coronavirus 2 infection in Italian pediatric oncology patients: a study from the Infectious Diseases Working Group of the Associazione Italiana di Oncologia e Ematologia Pediatrica. J. Pediatric Infect. Dis. Soc. 9, 530–534 (2020).
pubmed: 32652521
Mohammadi, A., Esmaeilzadeh, E., Li, Y., Bosch, R. J. & Li, J. Z. SARS-CoV-2 detection in different respiratory sites: a systematic review and meta-analysis. EbioMedicine 59, 102903 (2020).
pubmed: 32718896
pmcid: 7380223
Zhou, X., Zhou, J. & Zhao, J. Recurrent pneumonia in a patient with new coronavirus infection after discharge from hospital for insufficient antibody production: a case report. BMC Infect. Dis. 20, 500 (2020).
pubmed: 32652938
pmcid: 7352096
Ruark, J. et al. Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy. Biol. Blood Marrow Transpl. 26, 34–43 (2020).
Broome, H. E., Rassenti, L. Z., Wang, H. Y., Meyer, L. M. & Kipps, T. J. ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia. Leuk. Res. 35, r–1394 (2011).
Mueller, K. T. et al. Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia. Clin. Cancer Res. 24, 6175–6184 (2018).
pubmed: 30190371
pmcid: 7433345
Weissert, R. Progressive multifocal leukoencephalopathy. J. Neuroimmunol. 231, 73–77 (2011).
pubmed: 20937530
Brown, P. et al. Pediatric acute lymphoblastic leukemia, version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc Netw. 18, 81–112 (2020).
pubmed: 31910389
Maude, S. L. et al. Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children and young adults with relapsed/refractory acute lymphoblastic leukemia [abstract]. Blood. 128, 217 (2016).
Maude, S. L. et al. Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL [abstract]. J. Clin. Oncol. 34, 3011 (2016).
Lanza, F. et al. CD22 expression in B-cell acute lymphoblastic leukemia: biological significance and implications for inotuzumab therapy in adults. Cancers 12, 303 (2020).
pmcid: 7072635
Fry, T. J. et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat. Med. 24, 20–28 (2018).
pubmed: 29155426
Shah, N. N. et al. CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial. J. Clin. Oncol. 38, 1938–1950 (2020).
pubmed: 32286905
pmcid: 7280047
Neelapu, S. S. et al. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit ‘ALL’. Nat. Rev. Clin. Oncol. 15, 218 (2018).
pubmed: 29434334
pmcid: 6716606
Dufner, V. et al. Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab. Blood Adv. 3, 2491–2498 (2019).
pubmed: 31451445
pmcid: 6712531
Lund, C. C. The estimation of areas of burns. Surg. Gynecol. Obste 79, 352–358 (1944).